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ABSTRACT
Objective To examine the impact of antenatal
supplementationwithmultiplemicronutrientsorironand
folic acid compared with folic acid alone on birth weight,
duration of gestation, and maternal haemoglobin
concentration in the third trimester.
Design Cluster randomised double blind controlled trial.
Setting Two rural counties in north west China.
Participants 5828 pregnant women and 4697 live births.
Interventions Villages were randomised for all pregnant
women to take either daily folic acid (control), iron with
folicacid,ormultiplemicronutrientswitharecommended
allowance of 15 vitamins and minerals.
Main outcome measures Birth weight, length, and head
circumference measured within 72 hours after delivery.
Neonatalsurvivalassessedatthesixweekfollow-upvisit.
Results Birth weight was 42 g (95% confidence interval 7
to 78 g) higher in the multiple micronutrients group
compared with the folic acid group. Duration of gestation
was 0.23 weeks (0.10 to 0.36 weeks) longer in the iron-
folic acid group and 0.19 weeks (0.06 to 0.32 weeks)
longerinthemultiplemicronutrientsgroup.Iron-folicacid
was associated with a significantly reduced risk of early
preterm delivery (<34 weeks) (relative risk 0.50, 0.27 to
0.94, P=0.031). There was a significant increase in
haemoglobinconcentrationinbothiron-folicacid(5.0g/l,
2.0 to 8.0 g/l, P=0.001) and multiple micronutrients
(6.9 g/l, 4.1 to 9.6 g/l, P<0.001) groups compared with
folic acid alone. In post hoc analyses there were no
significant differences for perinatal mortality, but iron-
folicacidwasassociatedwithasignificantlyreducedearly
neonatal mortality by 54% (relative risk 0.46, 0.21 to
0.98).
Conclusion In rural populations in China antenatal
supplementation with iron-folic acid was associated with
longer gestation and a reduction in early neonatal
mortality compared with folic acid. Multiple
micronutrients were associated with modestly increased
birth weight compared with folic acid, but, despite this
weight gain, there was no significant reduction in early
neonatal mortality. Pregnant women in developing
countries need sufficient doses of iron in nutrient
supplements to maximise reductions in neonatal
mortality.
Trial registration ISRCTN08850194.
INTRODUCTION
Neonataldeathscontributegreatlytochildmortalityin
developing countries, and these deaths have steadily
increasedasapercentageofalldeathsofchildrenunder
the age of 5.
12 In China, by 2004 neonatal mortality
accounted for more than half of all deaths in children
under 5.
3 Low birthweight babies are at higher risk of
morbidity and mortality than those of normal birth
weight
4 and are also at risk of postnatal growth
retardation, with possible adverse long term effects
ontheirphysicalandcognitivedevelopment.
56Oneof
the major causes of low birth weight in developing
countries is the poor nutritional status of the mother
before and during pregnancy, resulting in restricted
fetal growth especially during the third trimester.
7
Poor quality diet and inadequate intake, combined
with increasednutrient requirementsfor placentaland
fetal growth, can lead to multiple micronutrient
deficiencies in pregnancy and contribute to higher
rates of low birth weight.
8 To address these multiple
deficiency states Unicef has proposed the use of
multiple micronutrient supplements in pregnancy
that provide the recommended individual intakes for
pregnant women.
9
China is the most populated developing country in
theworld,andtheprevalenceoflowbirthweightvaries
across different socioeconomic groups and areas. A
1999 survey of low birth weight in China showed a
prevalence of low birth weight of 7.6% and 11.8% in
“poor” and “very poor” counties, respectively.
10 With
an average prevalence of low birth weight of 5.9%, an
estimated 1.2 million low birthweight babies are born
in China every year.
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Ministry of Health in China is folic acid to prevent
congenital neural tube defects.
11 There are no specific
policiesorprogrammesforthedistributionofmultiple
micronutrient or iron-folic acid supplements during
pregnancy,eventodisadvantagedwomen.Toprovide
evidenceinChinatoformulatepublichealthpolicyon
nutrientsupplementationinpregnancyweconducteda
community based cluster randomised controlled trial
in a disadvantaged rural population. We assessed the
impact of iron-folic acid and multiple micronutrient
supplements during pregnancy, compared with folic
acid alone, on birth anthropometry, duration of
gestation, and maternal haemoglobin concentration
in the third trimester. We also conducted a post hoc
assessment of the impact of the supplements on
perinatal mortality, comprising stillbirths and early
neonatal deaths.
METHODS
Experimental design
The trial took place in two poor rural counties in
Shaanxi Province of north west China. A pilot study
found a low birth rate of 13% and 57% of women with
anaemia(haemoglobin<110g/l)inthethirdtrimester.
Because of the scale of this trial we allocated the same
treatment to all pregnant women in a given village. In
2001 in the first county there were 14 townships and
234 villages, and in the second county there were 20
townships and 327 villages. Randomisation of villages
wasstratifiedbycountywithafixedratiooftreatments
(1:1:1) and blocking of 15 to ensure geographical
balance with an approximately equal distribution of
treatments per township.
The randomisation schedule was generated off site
with a pseudo-random number generator in SAS
version 6 (SAS Institute, Cary, NC). A treatment
colour code was assigned to each village based on the
treatment allocation schedule. The treatment codes
wereopenedonlyoncealldatahadbeencollectedand
blinded analysis of the primary hypothesis was
completed.
Study population and sample size
Thestudysampleconsistedofallwomenresidentinthe
counties who became pregnant between August 2002
and January 2006 and who fulfilled trial selection
criteria (see below). Before the start of the trial, we
estimated that we needed a sample of 2255 eligible
pregnant women per treatment to detect a 25%
reduction in low birth weight between either iron-
folic acid or multiple micronutrient and folic acid
(control)groups,assumingatwotailedtest,withα=0.05
and β=0.20, and a prevalence of low birth weight of
9.3% (based on a three month sample in 2000 of births
fromacountyhospitalinthestudyarea).Weincreased
the sample size to 2480 pregnant women per group to
account for 10% fetal loss and loss to follow-up.
At the start of the trial we also expected that
recruitment would take 2.5 years, based on registered
live births in the counties in the previous year.
Recruitment was slower than expected, however,
because many births were in women who lived in
large cities in eastern China but who returned to their
village to give birth and register their child. After
3.5yearsthetrialsponsorrequestedthatrecruitmentbe
stopped because of limitations with funding. At that
stage, January 2006,we had recruitedand randomised
5828eligiblewomen.Weestimatedthatthissampleof
about 1900 women per treatment would provide 80%
power to detect a 50 g difference in birth weight
between either iron-folic acid or multiple micronu-
trients and folic acid (control) groups, assuming a two
tailed test, with α=0.05 and birth weight standard
deviation (SD) of 436 g (based on values observed
across all treatment groups). This sample size, how-
ever,onlyhad80%powertodetecta40%reductionin
lowbirthweightbetweentreatmentgroups,assuminga
two tailed test, with α=0.05 and a prevalence of low
birth weight of 4.6% (prevalence observed across all
treatment groups). It also had a similarly low power of
80% to detect a 50% reduction in early neonatal
mortality between treatment groups, assuming a two
tailedtest,withα=0.05and anearly neonatalmortality
rateof15per1000livebirths.Wedidnotadjustforthe
cluster randomised design in any of these estimates of
sample size.
Table 1 |Baseline characteristics of clusters, households, and participants by treatment group.
Figures are numbers (percentages) unless stated otherwise
Folic acid Iron-folic acid Multiple micronutrients
No of clusters 178 183 170
Mean (SD) population in
clusters in 2001
826 (502) 781 (434) 890 (515)
Mean(SD)birthsinclustersin
2001
6.8 (5.4) 6.5 (4.4) 7.6 (8.6)
Mean (SD) pregnancies/
cluster/year
6.3 (1.1) 6.3 (1.1) 6.0 (1.3)
Mean (SD) No of family
members/cluster
4.2 (0.77) 4.2 (0.81) 4.2 (0.89)
Maternal age (years):
Mean (SD) 24.8 (4.4) 24.8 (4.3) 24.8 (4.4)
15-19 152 (7.5) 153 (8.0) 160 (8.4)
20-24 950 (47.1) 875 (45.8) 867 (45.7)
25-29 564 (28.0) 567 (29.7) 555 (29.2)
30-34 312 (15.5) 277 (14.5) 276 (14.5)
≥35 39 (1.9) 40 (2.1) 41 (2.2)
Women’s education:
<3 years 133 (6.6) 100 (5.3) 118 (6.2)
Primary 527 (26.3) 495 (26.0) 542 (28.6)
Secondary 1087 (54.2) 1022 (53.7) 962 (50.8)
High school and above 259 (12.9) 288 (15.1) 271 (14.3)
Women’s occupation:
Farmer 1677 (83.9) 1563 (82.3) 1599 (84.8)
Other 322 (16.1) 337 (17.7) 287 (15.2)
Household wealth index:
Mean (SD) −0.03 (1.49) 0.07 (1.53) −0.03 (1.55)
Poorest third 665 (33.0) 600 (31.4) 671 (35.3)
Middle third 725 (35.9) 639 (33.4) 627 (33.0)
Richest third 627 (31.1) 673 (35.2) 601 (31.7)
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Village doctors, with support from the township
maternal and child healthcare workers, recruited
women by active surveillance for pregnancy in
w o m e no fr e p r o d u c t i v ea g e .A tt h es t a r tt h ev i l l a g e
doctor conducted a mini-survey of all women of
reproductive age living in their village to identify
thosewhowerelikelytobecomepregnant,including
newly married women, those not using contracep-
tion, or those who said they wanted a child. Trained
villagedoctorsobtainedinformedverbalconsentfor
pregnancymonitoring,andconsentingwomenwere
visitedeverymonthandaskedaboutthedateoftheir
last menstrual period. Women with periods delayed
by more than five days had a urine pregnancy test,
and confirmed pregnancies were reported to the
township maternal and child health worker. Preg-
nancies in women resident in the studied townships
or counties were passively detected at antenatal
clinics in local health facilities. If the diagnosed
pregnancywaslessthan28weeks’ gestation,trained
MCHstafffromtownshiphospitalssoughtinformed
verbal consent to participate in the trial from the
woman and her partner.
Newly identified pregnant women were inter-
viewed to record their sociodemographic status and
their menstrual, reproductive, medical, and family
history. Recruited pregnant women received three
free antenatal care checks, at which they were asked
about pregnancy complications and underwent a
physical examination including blood pressure and
weight measurement. Haemoglobin was measured at
the third antenatal check. Trained MCH staff, with
monitoringbyprojectstaff,collectedandrecordedall
the information collected during the pregnancy until
thesixweekfollow-upvisitinapregnancycarerecord
book, which served both as a clinical record and data
capture instrument.
Iron-folic acid
(n=1912, No of clusters=183)
Multiple micronutrients
(n=1899, No of clusters=170)
Folic acid
(n=2017, No of clusters=178)
Excluded (n=1316):
  Refused to participate (n=727):
    Concerned about family planning (n=344, 47%)
    Worried about side effects (n=162, 22%)
    Would rather wait for results (n=53, 7%)
    Suspect trial is drug advertisement (n=43, 6%)
    Considered supplements are drugs (n=21, 3%)
    Other (n=104, 14%)
  Not meeting inclusion criteria (n=498):
    Gestation >28 weeks (n=79, 16%)
    Take other supplements (n=27, 5%)
    Serious illness (n=12, 2%)
    Abnormal reproductive history (n=16, 3%)
    Plan to work out of county (n=364, 73%)
  Other reason (n=91)
Clusters excluded (n=30)
  Merged with other villages (n=30, 100%)
Lost to follow-up (n=46)
Withdrawn from trial (n=104):
  Nausea (n=42, 40%)
  Vomiting (n=35, 34%)
  Others (n=27, 26%)
Fetal loss (n=204):
  Spontaneous abortion (n=121, 59%)
  Induced abortion (n=78, 38%)
  Other medical conditions (n=5, 2%)
No pregnancies with birth outcome in
  7 clusters
Lost to follow-up (n=58)
Withdrawn from trial (n=103):
  Nausea (n=31, 30%)
  Vomiting (n=40, 39%)
  Others (n=32, 31%)
Fetal loss (n=186):
  Spontaneous abortion (n=108, 58%)
  Induced abortion (n=75, 40%)
  Other medical conditions (n=3, 2%)
No pregnancies with birth outcome in
  5 clusters
Lost to follow-up (n=29)
Withdrawn from trial (n=72):
  Nausea (n=26, 36%)
  Vomiting (n=28, 39%)
  Others (n=18, 25%)
Fetal loss (n=211):
  Spontaneous abortion (n=136, 64%)
  Induced abortion (n=73, 35%)
  Other medical conditions (n=2, 1%)
No pregnancies with birth outcome in
  1 cluster
Births in 1545 women (n=1558)
  Stillbirths (n=64, 4%)
  Live births (n=1494, 96%)
  Single live births (n=1469)
  Twin live births (n=22)
  Triplet live births (n=3)
Births in 1565 women (n=1584)
  Stillbirths (n=47, 3%)
  Live births (n=1537, 97%)
  Single live births (n=1499)
  Twin live births (n=38)
  Triplet live births (n=0)
Births in 1705 women (n=1722)
  Stillbirths (n=56, 3%)
  Live births (n=1666, 97%)
  Single live births (n=1636)
  Twin live births (n=30)
  Triplet live births (n=0)
Birth weight analysed (n=1406)
  Missing birth weight (n=88, 6%)
Gestation analysed (n=1494)
Neonatal survival analysed (n=1469, No of
  clusters=163)
Birth weight analysed (n=1470)
  Missing birth weight (n=67, 4%)
Gestation analysed (n=1537)
Neonatal survival analysed (n=1499, No of
  clusters=178)
Birth weight analysed (n=1545)
  Missing birth weight (n=121, 7%)
Gestation analysed (n=1666)
Neonatal survival analysed (n=1636, No of
  clusters=177)
Assessed for eligiblity (n=7144, No of clusters=561)
Randomised (n=5828, No of clusters=531)
Fig 1 | Participant flow chart
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Villageswererandomlyassignedforwomentoreceive
one of three daily antenatal supplements: multiple
micronutrients, iron-folic acid, or folic acid alone
(control). The multiple micronutrient supplements
were formulated to contain approximately the
WHO/Unicef recommended dietary allowances for
each of 15 minerals or vitamins asfollows: 30 mg iron,
400 µg folate, 15.0 mg zinc, 2.0 mg copper, 65.0 µg
selenium, 150.0 µg iodine, 800.0 µg vitamin A, 1.4 mg
vitaminB-1(thiamine),1.4mgvitaminB-2(riboflavin),
1.9mgvitaminB-6,2.6µgvitaminB-12,5.0µgvitamin
D,70.0mgvitaminC,10.0mgvitaminE,and18.0mg
niacin.
12 Iron-folic acid supplements contained 60 mg
iron(twicetheamountofelementalironinthemultiple
micronutrients) and 400 µg folic acid. The folic acid
supplement contained 400 µg of folic acid. The three
supplement types were produced by Beijing Vita
Nutritious Products, Beijing, China, and were of
identical appearance and packaged in blister packs.
At enrolment, each woman received a blister pack
containing 15 capsules with instructions to take one
capsule daily. The village doctor visited the women
every two weeks to provide more supplements and to
retrievetheusedblisterstripsandrecordthenumberof
remaining capsules. The number of supplements
consumedthroughoutthetrialwassummedtoestimate
compliance.
Measurement of outcomes
Hospital nursing staff measured birth weight within
onehourofdelivery.Inthesixcountyhospitalsandthe
three largest township hospitals (78% of birth weights)
birth weight was measured with an electronic scale
(type BD 585, Tanita, Dongguan, Guangdong Pro-
vince, China) with precision to the nearest 10 g. For
birthsinthe31smallertownshiphospitals(10%ofbirth
weights) and for home births (12% of birth weights)
birth weight was measured with a baby scale (type
RTZ-10A-RT, Wuxi Weigher Factory, Wuxi, China)
withprecisiontothenearest50g.Forhomedeliveries,
township maternal and child health staff visited the
womenathomewithin72hoursofdeliverytomeasure
the baby and gather information on delivery. We
excluded from analyses newborn anthropometry
collected later than 72 hours after birth. Low birth
weight was defined as <2500 g. Birth length was
measured to the nearest 1 mm by using a portable
measuring board with fixed head piece. Occipitofron-
talheadcircumferencewasmeasuredwithatapetothe
nearest 1 mm.
Gestational age at birth was measured as completed
daysbasedonthefirstdayofthelastmenstrualperiod,
obtained at the baseline interview. Preterm delivery
was defined as delivery before 37 completed weeks’
gestation and early preterm delivery as before
34weeks.Smallforgestationalagebabiesweredefined
asthosewhoseweightwasbelowthe10thcentileofthe
gestational age-sex specific US reference for fetal
growth.
13
Maternalhaemoglobinconcentrationwasmeasured
in capillary blood collected early in the third trimester
(gestation 28-32 weeks) from a subsample of 599
pregnant women with a birth outcome, who were
consecutivelyenrolledfrom6July2004to28October
2005.HemoCueportablespectrophotometers(Ängel-
holm, Sweden) were used to assay haemoglobin
concentration and were calibrated daily and all
measurements were made within the temperature
operatingrangeof thisdevice (15-30°C).We excluded
haemoglobin measurements collected before 6 July
2004becauseinwinterthesemeasurementsweretaken
below the operating range, potentially resulting in
incorrect values. Anaemia in the third trimester was
defined as haemoglobin <110 g/l.
14
Village doctors or hospital staff reported fetal losses
during pregnancy, birth outcome, delivery informa-
tion, and neonatal and maternal deaths; maternal and
child health staff recorded data with precoded struc-
tured forms. Neonatal survival was assessed at the six
week follow-up visit.
We defined perinatal deaths as stillbirths (fetuses
deliveredat28weeks’gestationorlaterwithnosignsof
life and recorded as occurring before the onset of or
during labour) plus early neonatal deaths (deaths
among liveborn infants occurring within seven days
of delivery). Neonatal deaths were defined as deaths
among liveborn infants occurring within 28 days of
delivery. Project staff re-interviewed all women who
had a stillbirthor neonatal death to check the reported
information and, for hospital or clinic deliveries, to
cross check with medical records.
Table 2 |Baseline characteristics at enrolment related to pregnancy by treatment group.
Figures are numbers (percentages) unless stated otherwise
Folic acid Iron-folic acid Multiple micronutrients
No of pregnant women 2017 1912 1899
Mean (SD)Noofpregnancies 1.6 (0.7) 1.6 (0.7) 1.6 (0.7)
Parity:
0 1223 (60.6) 1184 (61.9) 1178 (62.0)
1 714 (35.4) 669 (35.0) 657 (34.6)
≥2 80 (4.0) 59 (3.1) 64 (3.4)
Gestation (weeks):
Mean (SD) 13.8 (5.8) 13.6 (5.6) 13.9 (5.6)
<12 884 (43.8) 835 (43.7) 820 (43.2)
12-15 432 (21.4) 424 (22.2) 424 (22.3)
16-28 701 (34.8) 653 (34.2) 655 (34.5)
Height (cm):
No of women 1998 1897 1878
Mean (SD) 158.8 (5.1) 158.9 (5.2) 158.7 (5.3)
Weight (kg):
No of women 1970 1864 1846
Mean (SD) 52.5 (6.0) 52.7 (6.4) 52.7 (6.1)
BMI (kg/m
2):
No of women 1968 1863 1840
Mean (SD) 20.8 (2.2) 20.9 (2.3) 20.9 (2.2)
Mid-upper arm circumference (cm):
No of women 1983 1884 1872
Mean (SD) 23.1 (2.1) 23.2 (2.2) 23.2 (2.1)
RESEARCH
page 4 of 11 BMJ | ONLINE FIRST | bmj.comStatistical analysis
To assess the effectiveness of randomisation we
examined the baseline characteristics of the clusters
and the individual pregnant women across treatment
groups. A wealth index was constructed from an
inventory of 16 household assets or facilities with a
principalcomponentanalysismethod,
15andthisindex
was categorised into thirds as an indicator for the
poorest, middle income, and richest households. The
mean number of supplements consumed and treat-
ment compliance rates (percentage of days that
supplements were consumed) were also examined.
All analyses were conducted using the intention to
treatprinciple.Weincludedonlyliveborninfantsinthe
analysesofbirthanthropometrybecausemoststillborn
infants were not measured. We estimated mean
differences and 95% confidence intervals for birth
weight and gestation and adjusted for the effect of
randomisationbyvillagesusinggeneralisedestimating
equation linear models with an independent correla-
tion structure, which is a suitable modelling strategy
where there are more than 40 clusters per treatment
group.
1617 The adjusted mean differences in birth
weight, birth length, head circumference, and gesta-
tion, and their 95% confidence intervals, were com-
puted relative to the folic acid group. Similarly, we
calculated adjusted mean differences for newborn
anthropometry and gestation at birth and their 95%
confidence intervals to compare the multiple micro-
nutrient and the iron-folic acid groups. To adjust for
clusterrandomisation,we appliedgeneralisedestimat-
ing equation binomial regression models with log link
andexchangeablecorrelationstructurestoestimatethe
relativerisksand95%confidenceintervalsforlowbirth
weight,smallforgestationalage,pretermdelivery,and
anaemia with the folic acid group as the reference and
withmultiplebirthindicatorasacofactor,andsimilarly
to compare the multiple micronutrient and iron-folic
acid groups.
We analysed perinatal mortality only in singleton
birthstopreventbiasfromtheeffectofmultiplebirths,
which have higher mortality risk. We calculated rates
of stillbirth and perinatal death using the number of
pregnanciesat28weeks’gestationasthedenominator.
Neonatal death rates were calculated with the number
of live births as the denominator. Kaplan-Meier
survival analysis was used to estimate the survival
probabilitiesoflivebornsingletoninfantsfrombirthto
28 days and to compare survival across treatment
groups. To adjust for the cluster randomisation, we
applied generalised estimating equation binomial
regression models with log link and exchangeable
correlation structures to estimate the relative risks and
95% confidence intervals for stillbirth and perinatal
andneonataldeathrateswiththefolicacidgroupasthe
reference. Wald χ
2 tests assessed the overall effects of
the three treatments for each outcome. We used Stata
version 9.2 (Stata/SE 9.2 StataCorp, College Station,
TX) for all analyses.
RESULTS
Figure 1 shows the flow of participants through the trial.
Enrolment began on 1 August 2002 andcontinued until
9 July 2005; the last baby born to a trial participant was
on 24 January 2006, and all women completed the trial
by 28 February 2006. Over the 3.5 year period, there
were 7144 confirmed pregnancies from the monitored
population:727womenrefusedtoparticipateinthetrial,
498 did not meet the inclusion criteria, and 91 did not
participate for other reasons (fig 1). We enrolled and
randomised5828women,butofthese133womenwere
lost to follow up, 279 stopped taking supplements and
refused to continue to participate, and 601 had a
spontaneous or induced abortion or other medical
condition resulting in fetal loss. There were a total of
4650 pregnancies that resulted in at least one live birth.
There were 167 stillbirths, where birth weight was not
usually recorded. There were a total of 4697 live births;
birth weight was missing or was measured beyond 72
hours after birth in 276. There were 4421 (94%) live
births with birth weight available for analysis and 222
perinataldeaths.Thefinalrowofboxesinfigure1shows
the numbers included in the intention to treat analyses
Table 3 |Compliance* and number of doses of supplements consumed by treatment group
Folic acid Iron-folic acid Multiple micronutrients
No who gave birth 1705 1565 1545
No (%) who complied:
0-25 9 (0.6) 16 (1.0) 18 (1.2)
26-50 24 (1.4) 29 (1.9) 32 (2.1)
51-75 95 (5.6) 110 (7.0) 88 (5.7)
76-100 1577 (92.5) 1410 (90.1) 1407 (91.1)
Mean (SD) 93.4 (12.7) 91.9 (14.8) 92.6 (14.9)
No (%) of supplements consumed:
<90 105 (6.2) 85 (5.4) 106 (6.9)
91-119 181 (10.6) 160 (10.2) 154 (10.0)
120-179 684 (40.1) 638 (40.8) 630 (40.8)
≥180 735 (43.1) 682 (43.6) 655 (42.4)
Mean (SD) 165 (44) 166 (44) 165 (45)
*Compliance calculated by number of actual supplements consumed divided by number of supplements
expected to be consumed.
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Fig 2 | Cumulative mortality curves for infants from birth to
28 days by treatment. Log rank test of difference: P=0.055 for
three groups; 0.032 for iron-folic acid v folic acid; 0.077 for
multiple micronutrients v folic acid; 0.708 for multiple
micronutrients v iron-folic acid
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treatment groups, 7% of the women were enrolled in a
village other than their usual place of residence, and this
was usually their mother’s village.
The sociodemographic characteristics and the
anthropometric measurements at enrolment and the
cluster and individual level baseline characteristics
were balanced by treatment groups (table 1). The
reproductive history of the pregnant women was
similaracrossgroupsandreflectedChina’s“onechild
policy,” with 3585 (61.5%) women having their first
pregnancy (table 2). The percentage of women
delivering at home was balanced across treatment
groupswith9.4%(149)foriron-folicacidgroup,12.4%
(193) for the multiple micronutrients group, and
11.4% (195) for the folic acid only group. There were
47pairsoftwinsandonesetoftriplets.Thesemultiple
births were not balanced across the treatment groups,
with 19 pairs of twins (of 1584 births) in the iron-folic
acid group, 12 pairs of twins and one set of triplets (of
1558 births) in the multiple micronutrient group, and
17pairsoftwins(of1722births)inthefolicacidgroup
(P=0.031).
There was a high level of compliance with the
supplementation in alltreatmentgroups (table 3). The
mean number of doses of supplements consumed per
womenduringpregnancywas165,andthiswassimilar
in each group. About 6% of women consumed fewer
than 90 supplements during the pregnancy, and over
80% consumed more than 120 supplements.
Impact of nutrient supplementation on anthropometry
and gestation at birth
Theintraclustercorrelationcoefficientforbirthweight
was 0.03 (95% confidence interval 0.015 to 0.052).
Therewasnoevidenceofaneffectofiron-folicacidon
mean birth weight (P=0.17) but birth weight was
significantly higher (42 g, 7 to 78 g, P=0.019) in the
multiplemicronutrientsgroupcomparedwiththefolic
acid alone (table 4). The increase in birth weight
observed in the iron-folic acid and the multiple
micronutrient groups corresponded with reductions
intheriskoflowbirthweight(<2500g)comparedwith
folic acid alone of 19% (P=0.20) and 22% (P=0.14),
respectively. Ina post-hocanalysisofbabieswhowere
small for gestational age, there were no significant
differencesintheproportionacrossthethreetreatment
groups, although the proportion in the multiple
micronutrient group was slightly lower (table 4).
The intracluster correlation coefficient for gestation
at birth was 0.02 (0.004 to 0.036). Table 4 shows there
wasasignificantincreaseinthedurationofgestationof
0.23 weeks (0.10 to 0.36 weeks, P=0.001) in the iron-
folic acid group and 0.19 weeks (0.06 to 0.32 weeks,
P=0.004) in the multiple micronutrient group com-
paredwithfolicacid.Theincreaseinthemeanduration
of gestation in the iron-folic acid group corresponded
with a 21% reduction in the risk of preterm delivery
(<37weeks)(P=0.13)andasignificant50%reductionin
the risk of early pretermdelivery (<34 weeks) (relative
risk 0.50, 0.27 to 0.94, P=0.031). Compared with folic
acid alone, the increase in the mean duration of
g e s t a t i o no b s e r v e di nt h em u l t i p l em i c r o n u t r i e n t
group corresponded with non-significant reductions
in the risk of preterm delivery (<37 weeks) and early
pretermdelivery(<34weeks)of14%(P=0.29)and30%
(P=0.26), respectively (table 4).
The intracluster correlation coefficient for birth
length was 0.03 (0.007 to 0.047) and for head
Table 4 |Birthanthropometry,gestation,and haemoglobin,withadjusteddifferenceorrelative
risk for comparison of multiple micronutrients or iron-folic acid with folic acid alone
Birth outcomes
No (%*) of
infants Mean (SD)
Adjusted† difference or
relative risk (95% CI) P value
Birth weight (g)‡ ‡
Folic acid 1545 3153.7 (444.9)
Iron-folic acid 1470 3173.9 (424.4) 24.3 (−10.3 to 59.0) 0.169
Multiple micronutrients 1406 3197.9 (438.0) 42.3 (7.1 to 77.5) 0.019
Birth weight <2500 g
Folic acid 82 (5.3) —
Iron-folic acid 66 (4.5) — 0.81 (0.59 to 1.12) 0.199
Multiple micronutrients 57 (4.1) — 0.78 (0.56 to 1.08) 0.139
Small for gestational age
Folic acid 280 (18.1) —
Iron-folic acid 278 (18.9) — 1.04 (0.89 to 1.22) 0.618
Multiple micronutrients 238 (16.9) — 0.95 (0.82 to 1.12) 0.549
Gestation at birth (weeks)
Folic acid 1666 39.63 (1.93)
Iron-folic acid 1537 39.84 (1.69) 0.23 (0.10 to 0.36) 0.001
Multiple micronutrients 1494 39.82 (1.80) 0.19 (0.06 to 0.32) 0.004
Preterm <37 weeks
Folic acid 102 (6.1) —
Iron/folic acid 76 (4.9) — 0.79 (0.58 to 1.07) 0.131
Multiple micronutrients 78 (5.2) — 0.86 (0.64 to 1.14) 0.285
Early preterm <34 weeks
Folic acid 30 (1.80) —
Iron-folic acid 15 (0.98) — 0.50 (0.27 to 0.94) 0.031
Multiple micronutrients 19 (1.27) — 0.70 (0.38 to 1.30) 0.259
Birth length (cm)§ §
Folic acid 1367 48.8 (2.9)
Iron-folic acid 1299 49.1 (2.7) 0.24 (0.02 to 0.46) 0.032
Multiple micronutrients 1251 49.1 (2.8) 0.22 (−0.05 to 0.49) 0.117
Head circumference (cm)¶ ¶
Folic acid 1350 33.1 (1.6)
Iron-folic acid 1278 33.2 (1.6) 0.11 (−0.06 to 0.28) 0.207
Multiple micronutrients 1234 33.1 (1.6) 0.02 (−0.16 to 0.21) 0.8
Haemoglobin** (g/l)
Folic acid 218 105.3 (14.2)
Iron-folic acid 193 110.1 (14.8) 5.0 (2.0 to 8.0) 0.001
Multiple micronutrients 188 111.8 (14.1) 6.9 (4.1 to 9.6) <0.001
Anaemia¶ ¶ (<110 g/l)
Folic acid 133 (61.0) —
Iron-folic acid 87 (45.1) — 0.74 (0.61 to 0.91) 0.003
Multiple micronutrients 81 (43.1) — 0.72 (0.59 to 0.88) 0.001
*If applicable.
†Adjusted for multiple births and cluster randomisation in general estimating equation linear models.
‡Data missing for 121 in folic acid, 67 in iron-folic acid, 88 in multiple micronutrients.
§Data missing for 299 in folic acid, 239 in iron-folic acid, 243 in multiple micronutrients.
¶Data missing for 316 in folic acid, 260 in iron-folic acid, 260 in multiple micronutrients.
**In subsample of 599 pregnant women with birth outcome who were consecutively enrolled from 6 July 2004
to 28 October 2005.
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that in the iron-folic acid group there was a significant
increase in birth length (0.24 cm; 0.02 to 0.46 cm,
P=0.03) compared with folic acid alone. There was no
significant effect of iron-folic acid on mean head
circumference (P=0.21).There were no significant
effects of the multiple micronutrients on either mean
birth length (P=0.12) or mean head circumference
(P=0.80).
Compared with folic acid alone, the difference in
mean birth weight, adjusted for multiple births,
gestation at delivery, and cluster randomisation, was
12.6gfortheiron-folicacidand 31.0gforthe multiple
micronutrients, indicating that the extension of the
durationofgestationcontributedtoasimilarincrement
in mean birth weight for iron-folic acid (11.7 g) and
multiple micronutrients (11.3 g) compared with the
folic acid.
Impact of nutrient supplementation on maternal
haemoglobin concentration
Haemoglobin samples were available for 599 women
in the third trimester. The baseline characteristics for
these women were balanced across the treatment
groups, and there were no significant differences
between the women with and without haemoglobin
measurements.Alsotherewasnosignificantdifference
in the mean gestation at haemoglobintesting (P=0.54),
which was 32.0 weeks (SD 2.6), 31.9 weeks (SD 2.8),
and 32.2 weeks (SD 3.1) for the folic acid, iron-folic
acid, and multiple micronutrient groups, respectively.
There was a significant increase in haemoglobin
concentration with both iron-folic acid and multiple
micronutrients compared with folic acid (P=0.001 and
P<0.001, respectively). In both the iron-folic acid and
the multiple micronutrient groups, however, more
than 40% of the women were still anaemic in the third
trimester (table 4).
Impact of supplementation on perinatal mortality
Post hoc analyses showed no significant impact on the
riskofperinatalmortality(stillbirthsandearlyneonatal
mortality) either in the iron-folic acid (P=0.307) or in
multiple micronutrients group (P=0.336) compared
with folic acid (table 5).
Post hoc analyses also showed no effect of iron-folic
acid compared with folic acid on the stillbirth rate,
though there was a non-significant increase of 39%
(relative risk 1.39, 0.95 to 2.04) in the multiple
micronutrients group. When we combined all fetal
losses (spontaneous abortions and stillbirths), the rates
were 103.1/1000 pregnancies for folic acid, 93.7/1000
for iron-folic acid, and 111.3/1000 for multiple
micronutrients, indicating no evidence of an altered
riskfortotalfetallosseswithiron-folicacid(relativerisk
0.91, 0.74 to 1.12) or with multiple micronutrients
(1.15, 0.94 to 1.40) compared with folic acid.
Theposthocanalysesshowedareductionintherisk
of early neonatal mortality among infants born to
women randomised to receive either iron-folic acid or
multiple micronutrients comparedwith folic acid. The
magnitude of the reduction (54%) was significant for
theiron-folicacidgroup(relativerisk0.46,0.21to0.98)
compared with folic acid but not for the multiple
micronutrients group (29%; 0.71, 0.36 to 1.39).
Figure 2 illustrates cumulative mortality curves for
infantsfrombirthto28days,withlowermortalityrates
for neonates whose mothers received iron-folic acid
andmultiplemicronutrients.Mostofthedivergenceof
the mortality curves occurred in the first seven days
after birth, after which the curves were about parallel.
Theoveralldifferenceswereofborderlinesignificance
(P=0.055), but the difference between iron-folic acid
and folic acid alone was significant (P=0.032). The
other individual treatment comparisons (multiple
micronutrientsvfolicacidandmultiplemicronutrients
v iron-folic acid) were not significant (P=0.077 and
P=0.708, respectively).
Therewere73neonataldeaths,includingthreepairs
of twins. The highest number of neonatal deaths
because of preterm delivery was in the folic acid
group (11/73, 15.1%) with similar numbers for iron-
folic acid (5/73, 6.8%) and multiple micronutrients (6/
73, 8.2%) groups. There was also a higher number of
deathsfrombirthasphyxiainthefolicacidgroup(8/73,
11.0%) with the same number in the iron-folic acid (3/
73, 4.1%) and multiple micronutrient (3/73, 4.1%)
groups.
There were no significant differences between
multiple micronutrients compared with iron-folic
Table 5 |Mortality outcomes (in singleton births)
Folic acid Iron-folic acid Multiple micronutrients Relative risk (95% confidence interval)*
No in
group
Rate/
1000
No in
group
Rate/
1000 No in group Rate/1000
Iron-folic acid
v folic acid
Multiple micronutrients
v folic acid
Pregnancies with single live or stillbirth:
Total 1688 — 1546 — 1532 —— —
Stillbirths (≥ 28 weeks) 52 30.8 47 30.4 63 41.1 1.01 (0.67 to 1.51) 1.39 (0.95 to 2.04)
Live births 1636 — 1499 — 1469 —— —
All neonatal deaths 33 20.2 16 10.7 18 12.3 0.53 (0.29 to 0.97) 0.61 (0.34 to 1.10)
Early neonatal deaths 24 14.7 10 6.7 15 10.2 0.46 (0.21 to 0.98) 0.71 (0.36 to 1.39)
Perinatal deaths 76 45.0 57 36.9 78 50.9 0.84 (0.59 to 1.19) 1.18 (0.85 to 1.63)
*Adjusted for cluster randomisation with general estimating equation binomial model.
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haemoglobin concentration, or perinatal mortality.
On the basis of our results, the number of women
whowouldneedto betreatedwithiron-folicacidfrom
early in pregnancy would be 6.2 (6.1 to 6.3) to prevent
one case of maternal anaemia in the third trimester,
83.3(83.28to83.32)topreventonepretermdelivery<
37 weeks, 122 (121.99 to 122.01) to prevent one early
preterm delivery <34 weeks, and 125 (124.99 to
125.01) to prevent one early neonatal death. With
multiple micronutrients the numbers needed to treat
would be 5.6 (5.5 to 5.7), 111.1 (111.08 to 111.12),
188.7 (188.69 to 188.71), and 222 (222.19 to 222.21)
respectively.
DISCUSSION
Inthistrialtheresponsetonutrientsupplementationin
pregnancy varied by outcome. Compared with folic
acid alone, multiple micronutrient supplements were
significantly associated with increased birth weight,
whileiron-folicacidhadnosignificanteffect.Iron-folic
acid supplements were significantly associated with
increasedbirthlength.Therewasasignificantincrease
in the mean duration of gestation in both the iron-folic
acid and multiple micronutrients groups compared
with folic acid. In post hoc analyses, the iron-folic acid
and the multiple micronutrient supplements had no
significanteffectonperinatalmortality,buttherewasa
significant54%reductioninearlyneonatalmortalityin
women who received supplementation with iron-folic
acid compared with folic acid alone, but no significant
effects on stillbirths. Both multiple micronutrients and
iron-folic acid were associated with significantly
increased maternal haemoglobin concentration in the
third trimester compared with folic acid, although
nearly half of the women in these groups remained
anaemic. Overall, we have shown that antenatal
nutrient supplementation is associated with increased
maternal haemoglobin concentration in late preg-
nancy, mean birth weight, and duration of pregnancy
and reduced preterm delivery and early neonatal
mortality.
The effects of iron-folic acid and multiple micro-
nutrients on the duration of gestation and neonatal
mortality seem to be related to the iron in these
supplements. We tested the impact of two different
dosesofironinpregnancy—namely,60mgintheiron-
folic acid supplements and 30 mg in the multiple
micronutrient supplements. The largest impact on
neonatal mortality was with the supplement with the
highest dose of iron, and we saw a similar pattern for
duration of gestation and effects on preterm delivery.
In contrast, a recently reported large scale community
based trial from Indonesia found no significant
differences for neonatal mortality between daily
antenatalsupplementswithiron-folicacidandmultiple
micronutrients(WHO/Unicef formulationastestedin
China),whichbothhadthesamedoseofiron(30mg).
18
These findings from Indonesia suggest that the higher
neonatal mortality rate we observed in China with
multiple micronutrients compared with iron-folic acid
cannot be explained by the additional micronutrients
but by the different dose of iron in the supplements.
In our trial, the multiple micronutrient supplements
were associated with a significant increase in birth
weight compared with folic acid, but this did not
translate into significant reductions in neonatal mor-
tality. Rather the reduction in neonatal mortality
seemed to be related to the increased duration of
gestation and the reduced number of early preterm
deliveriesbecauseofironintheantenatalsupplements.
Evidence of an important role of antenatal iron
supplements in reducing preterm delivery has been
reported from the United States.
19 In the US trial,
antenatal iron (30 mg), was associated with a reduced
rate of preterm delivery (8% v 14%, P=0.05) and
increased mean birth weight (108 g, P=0.03). Long-
itudinal studies in Brazil
20 and Bangladesh
4 indicate
that preterm infants have much higher neonatal
mortality than babies with retarded intrauterine
growth or those born at term. In Bangladesh, a study
of birth outcomes among low birthweight infants
reported that 75% of the neonatal deaths were related
to preterm delivery.
4 These observational findings
suggestaplausiblereasonastowhytheincreasedmean
duration of gestation and reduced preterm delivery
(especially early preterm delivery) we observed could
be related to a large reduction in neonatal mortality.
Study strengths and limitations
This study was a double blind cluster randomised
controlled trial design with a balanced distribution of
confounders across treatment groups. Even though
randomisation was by village clusters, there were a
large number of clusters (531) with about 180 per
treatmentgroupandarelativelysmallnumberofbirths
in each cluster. Population recruitment of pregnancies
allowed complete tracing of fetal losses, including
spontaneousandinducedabortionsandstillbirths,and
pregnancy outcomes in both hospital and home
deliveries. We used appropriate statistical methods in
the data analysis that adjusted for the cluster randomi-
sation.
The location of the study in a socioeconomically
disadvantaged area of western China allowed us to
examine effects of nutrient supplements in a popula-
tion with the highest rates of low birth weight and
neonatal mortality in the country. Only 2.3% of the
enrolledwomenwerelosttofollow-up,and94%ofthe
liveborn infants were weighed within 72 hour of
delivery.Therewasnoevidenceofunder-enumeration
of neonatal deaths, with neonatal mortality rates in the
folic acid group (20.2/1000 live births) similar to those
reportedforequivalentruralcountiesfromthenational
maternal and child health surveillance system (22.5/
1000 live births).
3
The trial was adequately powered to detect small
changes in infant anthropometry at birth and the
duration of gestation, but one limitation was the low
power to detect changes in the prevalence of low birth
weight, preterm delivery, and perinatal mortality. The
mortalityanalyseswereposthocratherthanaprimary
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examine the effects of the different supplements on
mortality. For example, the non-significant reduction
in neonatal mortality associated with multiple micro-
nutrients might have been significant with a larger
sample. The outcome data were collected by the local
health service staff, although the research team did
providespecialtrainingonhowtomeasureandrecord
these outcome indicators for the trial.
The balance of treatments by area and therefore by
service providers reduced the likelihood of any
systematic differences in misclassification of stillbirths
and early neonatal deaths by treatment group. The
duration of gestation was measured by asking the
mother to recall the date of her last menstrual period.
The heightened awareness and knowledge about
reproduction because of the one child policy in
China, however, might have improved the accuracy
of the respondent’s recall of her last menstrual period
and other perinatal events.
Comparison with other studies
Our results help to explain the apparent increase in
neonatal and perinatal mortality reported from other
trials usingthe sameor similar formulationof multiple
micronutrient supplements compared with standard
iron-folic acid supplements.
21-23 In two trials from
Nepal multiple micronutrient supplementation was
associated with a non-significant increase in neonatal
and perinatal mortality compared with iron-folic
acid.
2122 In a pooled analysis of these trials neonatal
mortality(relativerisk1.52,1.03to2.25)andperinatal
mortality (1.36, 1.02 to 1.81) were significantly higher
in the multiple micronutrients group compared with
iron-folicacid.
23Thesefindingswereinterpretedbythe
authors as an increased risk of perinatal mortality with
multiple micronutrient supplements. Our findings
showed a significant reduction in neonatal mortality
foriron-folicacid(47%)andanon-significantreduction
for multiple micronutrients (39%) compared with folic
acid. The greater effect on mortality of iron-folic acid
compared with multiple micronutrients could account
for why comparisons of multiple micronutrients with
iron-folic acid give the appearance of an increased risk
of neonatal mortality.
There are similarities between our results and the
results of other earlier controlled trials of iron
supplementation in pregnancy.
2425 In Niger, a double
blind randomised controlled trial assessed the impact
of100mgironorplacebointhethirdtrimesteroniron
status of the mother and newborn and on the
anthropometric status of the newborn.
24 The iron
supplements were associated with significantly
decreased maternal iron deficiency at delivery and at
three months after delivery and increased the iron
status of the infants at 3 months. Birth length was
significantly higher and there was a non-significant
increase in birth weight in the iron supplemented
group. There were seven fetal and neonatal deaths in
the placebo group and one in the iron supplemented
group. In the US, a trial of iron supplementation
(30mg/day)versusplacebofrom11weeks’gestationin
pregnant women who were not anaemic reported a
significantly longer duration of gestation (0.6 weeks)
and fourfold reduction in the risk of preterm low birth
weight in the iron supplemented women.
25 Our
findings were also consistent with those from observa-
tionalstudiesthatreportedanincreasedriskofpreterm
deliveryinwomenwithirondeficiencyanaemiainthe
first trimester of pregnancy.
26-30 For example, an
analysis of perinatal data from Shanghai showed a
greater than twofold increase in the risk of low birth
weight and preterm delivery in women who had
moderate anaemia (90-99 g/l) and a greater than
threefold increase for women with severe anaemia
(<90 g/l) in the first trimester.
29
The absorption of iron during pregnancy is a
complex physiological process, with increasing rela-
tive absorption as gestation progresses but with a
decrease in the percentage of the dose absorbed as the
total dose increases.
31 In our trial, even though the
amount of iron in the iron-folic acid supplement was
twice the amount in the multiple micronutrient
supplement this would not necessarily have led to
twice the absorption of iron and therefore twice the
dose of iron. The vitamin C in the multiple micro-
nutrientsupplementsmighthaveenhancedtheabsorp-
tion of iron and also contributed to reducing the
difference in the absolute amount of iron absorbed.
The response of haemoglobin concentration to the
iron-folicacidandmultiplemicronutrientswassimilar,
but the associated neonatal mortality seemed to be
proportionate to the likely relative amount of iron
contained in each supplement.
We observed a larger birth weight response in the
multiple micronutrients group than in the iron-folic
acidgroup.Thisfindingwassimilartothatobservedin
other trials comparing iron-folic acid and multiple
micronutrients,but thetotalincreaseinbirth weightin
our multiple micronutrients group compared with
iron-folicacidgroupwaslessthanthatreportedinother
studies.
223233 Thisdidnot translateinto lowerneonatal
mortality, although it implies improved fetal growth
and development, which might confer other health
WHAT IS ALREADY KNOWN ON THIS TOPIC
Neonatal deathsremaina major causeofchild mortality inthose agedunder 5 indeveloping
countries and are associated with low birth weight
One of the major causes of low birth weight in developing countries is the poor nutritional
status of the mother before and during pregnancy
WHAT THIS STUDY ADDS
Antenatal iron-folic acid increases the duration of gestation, reduces early preterm delivery,
and is associated with a significant reduction in early neonatal mortality compared with folic
acid alone
Antenatalmultiplemicronutrientsmodestlyincreasebirthweightcomparedwithfolicacidbut,
despite this weight gain, are not associated with reduced early neonatal mortality
An adequate dose of iron is required in micronutrient supplements for pregnant women to
maximise reductions in neonatal mortality in developing countries
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growth, boosted immune responses, and enhanced
cognitive development.
We have shown that micronutrient supplements
have important health effects for the newborn infant,
with a potential to increase birth weight and birth
length through increased duration of gestation and
direct effects on fetal growth. Reduced neonatal
mortality seems to be a response to the iron in the
supplements,possiblymediatedbyincreasedduration
of gestation and lower rates of preterm delivery. We
cannotrecommendthatmultiplemicronutrientsatthe
currently proposed dose
12 should replace standard
iron-folicacid supplementsin pregnancybecause they
seem to provide less protection against preterm
delivery and neonatal deaths in populations where
iron deficiency in pregnancy is common. An adequate
dose of iron is required in micronutrient supplements
for pregnant women in developing countries to
maximise reductions in neonatal mortality.
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